---
title: "Akili Interactive Labs, Inc. — Publisher Overview"
type: publisher
publisher: "Akili Interactive Labs, Inc."
publisher_slug: "akili-interactive-labs-inc"
canonical_url: "https://marlvel.ai/publishers/akili-interactive-labs-inc"
last_updated: 2026-04-24T05:28:02.568Z
source: Marlvel.ai
license: CC-BY-NC-4.0
citation: "Marlvel.ai — Akili Interactive Labs, Inc. Publisher Overview"
---
## ⚠ Content Warning

This publisher's portfolio includes apps classified as sensitive (kids, health, adult). Information is aggregated from public sources for informational purposes only. This publisher has apps marketed to children. This overview is provided to inform parents, guardians, or professionals — not to promote the apps to minors.

---

# Akili Interactive Labs, Inc. — Publisher Overview

> Providing FDA-authorized and clinically-designed game-based digital therapeutics to improve attention and focus for individuals with ADHD.

- **Publisher:** Akili Interactive Labs, Inc.
- **Website:** [https://endeavorotc.com](https://endeavorotc.com)
- **Overview generated:** 2026-04-24
- **License:** CC-BY-NC 4.0

## Executive summary

Akili Interactive has established a unique moat by bridging the gap between consumer gaming and regulated medical devices, securing the first-ever FDA authorization for a prescription video game. Their strategy leverages a dual-track distribution model: a prescription-based clinical path for pediatric patients and a direct-to-consumer subscription model for adults. This regulatory-first approach creates a significant barrier to entry for traditional app developers while positioning them as a leader in the emerging digital therapeutics (DTx) category.

## Publisher DNA

- **Primary focus:** Game-based digital therapeutics for ADHD
- **Scale:** indie
- **Target audience:** Adults with ADHD and parents/caregivers of children (8-17) seeking non-pharmacological, clinically-validated cognitive treatments.

## Portfolio momentum

- **Velocity:** steady
- **Active apps:** 3
- **Abandoned apps:** 2
- **Last major release:** 57 days ago

Maintained 3 active apps with 2 updates in the last 6 months, focusing development on their flagship adult and pediatric treatments.

## Aggregated portfolio metrics

- **Total reviews (all apps):** 3,056
- **Weighted rating:** 3.99 / 5
- **Apps in portfolio:** 5

## Category breakdown

| Category | Apps | Share |
| :--- | :--- | :--- |
| Medical | 5 | 100% |

## Top apps

- **EndeavorOTC®: Outplay ADHD** — Flagship consumer title — 1,628 reviews, subscription-based adult treatment.
- **EndeavorRx® - Kid** — FDA-authorized prescription treatment for children aged 8-17.
- **EndeavorRx Insight®** — Highest-rated app — 4.4 stars companion tool for treatment monitoring.

## Signature patterns

- Utilization of proprietary Selective Stimulus Management Engine (SSME™) technology across core products
- Focus on game-based mechanics to deliver cognitive tasks and clinical interventions
- Multi-tier access models including prescription-only, direct subscription, and free companion tools
- Heavy emphasis on data-driven progress tracking via proprietary 'Focus Score' metrics
- Strict adherence to clinical and regulatory frameworks within the Medical category

## Bottom line

Akili Interactive is a pioneer in the digital therapeutics space, successfully commercializing regulated medical software through a gamified interface. Their ability to navigate FDA pathways while maintaining consumer-grade engagement makes them the primary incumbent in the prescription-digital-treatment market.

---
© 2026 Marlvel.ai | [Publisher apps index](https://marlvel.ai/api/llm/publishers/akili-interactive-labs-inc) | [Methodology](https://marlvel.ai/api/llm/methodology)
Data licensed under CC-BY-NC 4.0.

---
© 2026 Marlvel.ai | [Full publisher profile](https://marlvel.ai/publishers/akili-interactive-labs-inc) | [Publisher apps index](https://marlvel.ai/api/llm/publishers/akili-interactive-labs-inc) | [Methodology](https://marlvel.ai/api/llm/methodology)
Data licensed under CC-BY-NC 4.0.